Literature DB >> 11023187

Effects of interaction between Escherichia coli verotoxin and lipopolysaccharide on cytokine induction and lethality in mice.

Kuri Suzuki, Kazuhiro Tateda1, Tetsuya Matsumoto1, Fumio Gondaira1, Shirou Tsujimoto1, Keizo Yamaguchi1.   

Abstract

In Escherichia coli 0157 infections, verotoxins (VT) play a critical role in causing the disease, although other factors such as lipopolysaccharide (LPS) and inflammatory cytokines may affect the progression and course of the disease. The present study examined the roles of VT and LPS in induction of serum cytokines and lethality in mice. LD50 of VT2 (13 ng) was c. 10(4)-fold smaller than that of LPS (400 microg). Although the lethal toxicity of these toxins was examined in several experimental conditions, such as VT2 (5, 10, 20, 40 ng/mouse) alone or in combination with LPS (100 microg/mouse) at various times (-2 days to +2 days), no evidence of synergy was observed. VT2 did not augment LPS-induced tumour necrosis factor-alpha (TNF-alpha) or interleukin-6 production, and conversely suppressed TNF-alpha production when it was injected 2 days before LPS challenge. The data failed to indicate either synergic or additive effects of VT and LPS on cytokine production or lethality in mice. In contrast, antagonistic interactions were clearly observed in cytokine production in certain conditions. The results suggested that these toxins may be co-operatively involvedin the pathology of VT-related diseases, but not through synergic interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023187     DOI: 10.1099/0022-1317-49-10-905

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Protective effects of chelerythrine against lipopolysaccharide-induced endotoxic shock in mice.

Authors:  Xiaofeng Niu; Qingli Mu; Weifeng Li; Huimin Huang; Huan Yao; Huani Li
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

2.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

3.  Lipopolysaccharide-induced inhibition of transcription of tlr4 in vitro is reversed by dexamethasone and correlates with presence of conserved NFκB binding sites.

Authors:  Camila P Bonin; Raquel Y A Baccarin; Katarina Nostell; Laila A Nahum; Caroline Fossum; Maristela M de Camargo
Journal:  Biochem Biophys Res Commun       Date:  2013-02-10       Impact factor: 3.575

4.  Shiga toxin 2 targets the murine renal collecting duct epithelium.

Authors:  Mitchell A Psotka; Fumiko Obata; Glynis L Kolling; Lisa K Gross; Moin A Saleem; Simon C Satchell; Peter W Mathieson; Tom G Obrig
Journal:  Infect Immun       Date:  2009-01-05       Impact factor: 3.441

5.  Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity.

Authors:  Xiangdong Wang; Jing Jiang; Jason Warram; Gerhard Baumann; Yujun Gan; Ram K Menon; Lee A Denson; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2008-03-06

6.  Pharmacokinetic and anti-inflammatory effects of sanguinarine solid lipid nanoparticles.

Authors:  Weifeng Li; Huani Li; Huan Yao; Qingli Mu; Guilan Zhao; Yongmei Li; Hua Hu; Xiaofeng Niu
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

Review 7.  Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection.

Authors:  Krystle L Mohawk; Alison D O'Brien
Journal:  J Biomed Biotechnol       Date:  2011-01-03

8.  Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2.

Authors:  Thomas P Griener; Jonathan G Strecker; Romney M Humphries; George L Mulvey; Carmen Fuentealba; Robert E W Hancock; Glen D Armstrong
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.